Li C, Fan L, Lin C, Hu C, Chiu M
ACS Omega. 2025; 10(7):7256-7263.
PMID: 40028141
PMC: 11865983.
DOI: 10.1021/acsomega.4c10879.
Futacsi A, Rusznak K, Szarka G, Volgyi B, Wiborg O, Czeh B
Front Aging Neurosci. 2025; 17:1542229.
PMID: 40013092
PMC: 11860898.
DOI: 10.3389/fnagi.2025.1542229.
Bjerkan J, Meglic B, Lancaster G, Kobal J, McClintock P, Crawford T
Brain Commun. 2025; 7(1):fcaf007.
PMID: 40008330
PMC: 11852277.
DOI: 10.1093/braincomms/fcaf007.
Ferreira da Silva A, Gomes A, Goncalves L, Fernandes A, Almeida A
Pharmaceutics. 2025; 17(2).
PMID: 40006510
PMC: 11858903.
DOI: 10.3390/pharmaceutics17020141.
Arafi P, Devkota S, Williams E, Maesako M, Wolfe M
Elife. 2025; 13.
PMID: 39932776
PMC: 11813224.
DOI: 10.7554/eLife.102274.
Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge.
Darabi S, Charkhat Gorgich E, Moradi F, Rustamzadeh A
IBRO Neurosci Rep. 2025; 18:191-199.
PMID: 39906286
PMC: 11791331.
DOI: 10.1016/j.ibneur.2025.01.004.
A network aggregation model for amyloid- dynamics and treatment of Alzheimer's diseases at the brain scale.
Brennan G, Goriely A
J Math Biol. 2025; 90(2):22.
PMID: 39891738
PMC: 11787187.
DOI: 10.1007/s00285-024-02179-5.
A 3D-induced pluripotent stem cell-derived human neural culture model to study certain molecular and biochemical aspects of Alzheimer's disease.
Prasannan P, Siney E, Chatterjee S, Johnston D, Shah M, Mudher A
In Vitro Model. 2025; 1(6):447-462.
PMID: 39872613
PMC: 11756488.
DOI: 10.1007/s44164-022-00038-5.
Olfactory dysfunction as potential biomarker in neurodegenerative diseases: a narrative review.
De Cleene N, Schwarzova K, Labrecque S, Cerejo C, Djamshidian A, Seppi K
Front Neurosci. 2025; 18():1505029.
PMID: 39840019
PMC: 11747286.
DOI: 10.3389/fnins.2024.1505029.
EBP1 potentiates amyloid β pathology by regulating γ-secretase.
Kim B, Hwang I, Ko H, Kim Y, Kim H, Seo S
Nat Aging. 2025; .
PMID: 39779912
DOI: 10.1038/s43587-024-00790-1.
Sodium Thiosulfate: An Innovative Multi-Target Repurposed Treatment Strategy for Late-Onset Alzheimer's Disease.
Hayden M, Tyagi N
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770582
PMC: 11676759.
DOI: 10.3390/ph17121741.
Essential role of sulfide oxidation in brain health and neurological disorders.
Kanemaru E, Ichinose F
Pharmacol Ther. 2024; 266:108787.
PMID: 39719173
PMC: 11806942.
DOI: 10.1016/j.pharmthera.2024.108787.
Physiopathological mechanisms underlying Alzheimer's disease: a narrative review.
Engelhardt E, Resende E, Gomes K
Dement Neuropsychol. 2024; 18:e2024VR01.
PMID: 39697643
PMC: 11654088.
DOI: 10.1590/1980-5764-DN-2024-VR01.
Neuroinflammation in Alzheimer disease.
Heneka M, van der Flier W, Jessen F, Hoozemanns J, Thal D, Boche D
Nat Rev Immunol. 2024; .
PMID: 39653749
DOI: 10.1038/s41577-024-01104-7.
Comparison between DSQIID total / sub-item scores and plasma p-tau elevation in adults with Down's syndrome.
Shinomoto M, Takeuchi C, Tatebe H, Kitani-Morii F, Ohmichi T, Fujino Y
PLoS One. 2024; 19(12):e0311878.
PMID: 39652530
PMC: 11627409.
DOI: 10.1371/journal.pone.0311878.
and Chronic Health Risk Factors are Associated with Sex-Specific Preclinical Alzheimer's Disease Neuroimaging Biomarkers.
Losinski G, Key M, Vidoni E, Clutton J, Morris J, Burns J
medRxiv. 2024; .
PMID: 39606325
PMC: 11601779.
DOI: 10.1101/2024.11.21.24317732.
Alzheimer's Disease from Modeling to Mechanism Research.
Sun X, Zhang W
Adv Neurobiol. 2024; 41:153-170.
PMID: 39589714
DOI: 10.1007/978-3-031-69188-1_7.
Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia research.
Ibanez L, Liu M, Beric A, Timsina J, Kohlfeld P, Bergmann K
Alzheimers Dement. 2024; 21(2):e14413.
PMID: 39575871
PMC: 11848383.
DOI: 10.1002/alz.14413.
Pharmacological inhibition of PLK2 kinase activity mitigates cognitive decline but aggravates APP pathology in a sex-dependent manner in APP/PS1 mouse model of Alzheimer's disease.
Martinez-Drudis L, Berard M, Musiol D, Rivest S, Oueslati A
Heliyon. 2024; 10(20):e39571.
PMID: 39498012
PMC: 11532864.
DOI: 10.1016/j.heliyon.2024.e39571.
Evaluating the robustness of DTI-ALPS in clinical context: a meta-analytic parallel on Alzheimer's and Parkinson's diseases.
Costa T, Manuello J, Premi E, Mattioli I, Lasagna L, Lahoz C
Sci Rep. 2024; 14(1):26381.
PMID: 39487289
PMC: 11530450.
DOI: 10.1038/s41598-024-78132-9.